Clinical Trial Update: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of KPT-8602 (eltanexor) in participants with relapsed/refractory cancer indications completed, evaluating safety, tolerability, and e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Castration-resistant Prostate Cancer
• Colorectal Cancer
• Higher-risk Myelodysplastic Syndrome
• Intermediate High-risk Myelodysplastic Syndrome
• Multiple Myeloma

Drugs mentioned

• KPT-8602 (eltanexor) (eltanexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Relapsed/Refractory Multiple Myeloma (RRMM), Metastatic Colorectal Cancer (mCRC) | Phase 1, Phase 2 | Status: COMPLETED